28 results about "Ion transporter" patented technology

To provide artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types.SOLUTION: An artificial expression construct comprises: (i) a concatemer of a specific sequence; (ii) a promoter; and (iii) a heterologous encoding sequence. The heterologous encoding sequence encodes an ion transporter, enzyme, transcription factor, receptor, membrane protein, cellular trafficking protein, signaling molecule, neurotransmitter, calcium reporter, channel rhodopsin, or CRISPR / CAS molecule etc., associated with a capsid that crosses the blood brain barrier. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in excitatory cortical neurons, such as primarily within cortical layers 2 / 3, 4, 5, and 6 and including those with extratelencephalic (ET) projections, intratelencephalic (IT) projections, and pyramidal tract (PT) projections.SELECTED DRAWING: None

This invention belongs to the field of pharmaceutical technology and discloses small organic molecules for reducing copper overload toxicity and their applications. Specifically, it discloses four small organic molecules for reducing copper overload toxicity and methods for doing so. These four small organic molecules are not copper chelators and do not reduce intracellular copper levels, thus not affecting the activity of copper-related enzymes. Furthermore, these four small organic molecules are not copper ion transporters and do not transport copper into cells, thus not exacerbating the cytotoxicity of copper overload.

The invention belongs to the technical field of medicines, and discloses an organic small molecule for reducing copper overload toxicity and application thereof. The invention specifically discloses four small organic molecules for reducing the overload toxicity of copper and a method for reducing the overload toxicity of copper. The four small organic molecules are not copper chelating agents and cannot reduce the copper level in cells, so that the copper-related enzyme activity cannot be influenced. Meanwhile, the four small organic molecules are not copper ion transporters and cannot transport copper into cells, so that the cytotoxicity of copper overload cannot be aggravated.

The invention discloses a method for inducing cell copper death based on GK921 and application of the GK921, and relates to the technical field of biological medicine. The invention discloses a brand new function of inducing copper death by a known compound GK921 for the first time, and provides a brand new strategy for solving the problems of drug resistance and relapse of multiple myeloma. According to the method, target cells are treated with an effective amount of GK921, expression of copper ion transporter ATP7A in the cells is specifically reduced, copper ions are accumulated, and then typical copper death events such as iron-sulfur cluster protein reduction and DLAT protein oligomerization are caused. Experiments show that the GK921 can efficiently inhibit the activity of multiple myeloma cell lines and primary cells, and the IC50 value and the low toxicity to normal cells show excellent selectivity. On the basis, GK921 can be used for preparing a pharmaceutical composition for inducing copper death, and particularly has an important application prospect in treatment of multiple myeloma.

The invention discloses a research method of 18beta-glycyrrhetinic acid on high-fat daily ration induced mitochondrial function injury mediated liver injury, which comprises the following steps: S1, test design, S2, test sample collection, S3, index determination, S4, test data statistical analysis, and S5, results, and the research method for 18beta-glycyrrhetinic acid (18beta-glyrhetinic acid, 18beta-glyrhetinic acid, 18beta-glyrhetinic acid, 18beta-glyrhetinic acid, 18beta-glyrhetinic acid, 18beta-glyrhetinic acid, 18beta-glyrhetinic acid, 18beta-glyrhetinic acid, 18beta- The liver injury of the micropterus salmoides caused by high fat ration (HF) can be improved by lowering TGF beta1-Smad2 / 3 signals to reduce aggregation of liver collagenous fibers, and the GA can activate Ampk-Pgc1alpha-Sirt3 signal pathways to reduce expression of calcium ion transporters in endoplasmic reticulum and mitochondria, relieve liver mitochondrial injury and reduce the content of ROS (reactive oxygen species), so that the liver injury of the micropterus salmoides caused by high fat ration (HF) can be relieved, and the liver injury of the micropterus salmoides caused by high fat ration (HF) can be relieved. And the HF can increase the activity of liver function related enzymes of the micropterus salmoides and increase liver lipid droplet deposition and collagen aggregation, and after the GA is added, the adverse effect caused by the HF can be obviously improved, so that the HF-induced liver injury of the micropterus salmoides can be relieved.

The invention relates to the technical field of feeds, in particular to a dietary dog food for recuperating gastrointestinal tracts of dogs and a preparation method thereof, and the dietary dog food comprises a basic nutritional agent, a gastric regurgitation preventing agent, a magnesium-zinc absorption promoting agent and a preservative. The modified sodium alginate forms gel in the stomach of the dog, sodium bicarbonate is decomposed to generate carbon dioxide gas to push the gel to float upwards to the cardia to form a shielding layer, and the modified cellulose releases calcium ions to promote crosslinking of the modified sodium alginate to form a more compact shielding layer so as to prevent backflow of contents in the stomach of the short-nose dog after the short-nose dog eats. The active form of vitamin D3 is combined with a vitamin D receptor in intestinal epithelial cells, gene expression of channels and ion transporters is up-regulated, and the absorption effect of dogs on magnesium and zinc in a high-calcium environment is promoted. The fructo-oligosaccharide enhances the signal transduction efficiency of the vitamin D3 by up-regulating the expression level of a vitamin D receptor, and further enhances the promotion effect of the vitamin D3 on magnesium and zinc absorption.

The invention discloses a bacillus cereus strain and application thereof, a phylogenetic tree is constructed through whole genome sequencing according to housekeeping genes, the phylogenetic tree is determined to belong to bacillus cereus (Bacillus cereus), and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34800. The strain B2 obtained through separation can secrete indoleacetic acid (IAA), IAA serves as auxin and is beneficial for stimulating plant root development and promoting root growth, so that the water and nutrient absorption capacity of plants is enhanced, the adaptability of the plants in a stress environment is improved, meanwhile, the strain B2 can regulate and control sodium and potassium ion transport in pepper plants, and the yield of the pepper plants is increased. Specifically, the expression level of the key ion transporter gene in the pepper is up-regulated. The bacillus cereus strain B2 is an efficient microbial resource and can be used for developing a microbial inoculant or a biological fertilizer so as to promote growth of crops such as capsicum in salinized soil, improve the salt resistance of the crops and guarantee and improve the sustainable production capacity of capsicum in the salinized soil.

The present invention relates to an African clawed frog oocyte expression vector pGXBG. X.lavies oocytes are widely used for protein expression and ion transporter identification in structural biology, developmental biology, electrophysiology and neurobiology. However, the vector cRNA translation efficiency of the existing restriction enzyme ligation or Gateway cloning method is not stable enough, and experiments cannot be strictly repeated. The present invention improves the translation efficiency by updating the Kozak sequence in the vector pGEMHE and creating a new X.lavies oocyte expression vector pGXBG series. Further TEVC experiments in X.lavies oocytes prove that the vector of the present invention provides a more stable and higher cRNA translation efficiency by expressing channel proteins in X.lavies oocytes to record larger and more stable current amplitudes.

A system and method to control the Na / K pumps for the treatment of ischemia of the kidney by providing an energy generating synchronization modulation electric field that is effective in synchronizing the Na / K pumps down to individual steps throughout the pumping cycle and in synthesizing one ATP for each pumping cycle. The generated ATP molecule compensates the ATP consumed in extrusion of 3 Na ions and pumping 2 K ions, resulting in a net-consumption of ATP for the Na / K pumps controlled by the system and method of the present invention that is significantly reduced, theoretically to zero, thereby providing an effective treatment for ischemia of the kidney.

[Problem] Changing the rearing environment of fish from freshwater to saltwater or from saltwater to freshwater requires fish to quickly adapt to the new environment. Therefore, there has been a need for an evaluation method for evaluating in advance whether fish prior to changing the rearing environment have the ability to adapt to the new environment. [Solution] A method for evaluating the saltwater adaptability of fish that includes a step for examining the expression of a gene of the fish, wherein the gene is a control factor of an ion transporter participating in saltwater adaptation and / or a control factor of an ion transporter participating in freshwater adaptation.

A system and method for controlling active ion transporters, such as sodium-potassium (Na / K) pumps to actively transports 3 Na+ and 2 K+ ions by consuming one ATP. The system and method provide an oscillating electric field that is effective in running the active ion-transport at their physiological running mode by consuming one ATP molecule to actively transport ion and to synthesize one ATP for each pumping cycle. The ATP molecule that is synthesized compensates for the ATP molecule that is consumed in actively transporting ions, resulting in a net-consumption of ATP that is significantly reduced, theoretically to zero.

The present invention provides a photo-controlled chloride ion transporter based on azobenzene semi-aza-calixarene, and its preparation method and application, belonging to the technical field of artificial ion transporters. The photo-controlled chloride ion transporter based on azobenzene semi-aza-calixarene provided by the present invention is composed of an azobenzene unit and a calixarene skeleton; the calixarene is a macrocyclic molecule composed of six N,N-dimethylglycoluril units, and the methylene group facing the inside of the ring effectively binds and transports anions through the ion-dipole interaction of the C-H bond with the anion, and both ends of the ring are covalently connected to the azobenzene through carbon chains of different lengths. The semi-aza-calixarene chloride ion transporter provided by the present invention has high chloride ion transport efficiency and high photo-responsive characteristics, and can efficiently achieve E / Z isomerization under the switching stimulation of ultraviolet / visible light in the external environment, realizing effective photo-controlled anion transmembrane transport.

Provided in the present invention are a manganese ion transporter (MntP) protein mutant and a recombinant strain expressing the mutant for high-yield L-threonine production. The mutant has an amino acid sequence as shown in SEQ ID NO: 2, which is obtained by means of mutating glycine (G) at position 25 to aspartic acid (D) in a wild-type MntP protein sequence as shown in SEQ ID NO: 1. By means of homologous recombination, the mutant is introduced into an Escherichia coli strain, providing the constructed recombinant strain with an increased yield of L-threonine.

The present invention discloses a monoclonal antibody specifically binding to Staphylococcus aureus manganese ion transporter C and its application. The antibody MntC-15 provided by the present invention can specifically bind to the MntC protein, can effectively inhibit the growth of Staphylococcus aureus, can resist sepsis caused by MRSA infection, and inhibit the release of mouse spleen lymphocyte cytokines induced by MntC, and has broad application prospects in clinical practice.

The invention discloses engineering saccharomycetes for selectively recovering waste valuable metals as well as a construction method and application of the engineering saccharomycetes. The tested microorganism is saccharomyces cerevisiae and comprises a gene for coding an exogenous metal ion transport protein, an inducible promoter and a terminator, and the promoter is galactose GAL1; and the terminator is CYC1 (Cytochrome CYC1). According to the invention, metal ion transport protein, metabolic pathway regulation, biomineralization and other synthetic biological tools are utilized, so that the recovery selectivity of valuable metals is improved; a biological system is mild in culture, can adapt to a relatively complex wastewater environment, and is beneficial to large-scale industrial operation; and a green and low-cost preparation mode is provided for preparation of high-added-value products. In a coexistence environment, the engineering yeast selectively recovers valuable metal Cd and synthesizes CdSe quantum dots of 92.20 mg / g dry yeast, and the CdSe quantum dots are 1.29 times that of wild saccharomyces cerevisiae. The system has the advantages of high selectivity, low cost, environmental friendliness and the like, and is suitable for metal resource utilization of electronic wastes, industrial wastewater and other scenes.

The invention relates to the technical field of solid-state batteries, in particular to a flame-retardant composite solid-state electrolyte and a preparation method and application thereof.The preparation method of the flame-retardant composite solid-state electrolyte comprises the steps that carbonic ester polymeric monomers, polymeric monomers containing amide groups and lithium salt are mixed, and a monomer solution is obtained; mixing the monomer solution with an inorganic electrolyte and an initiator to obtain a composite electrolyte precursor solution; and loading the composite electrolyte precursor solution on the polyimide porous membrane, and carrying out in-situ curing treatment to obtain the flame-retardant composite solid electrolyte. A polyimide porous membrane is used as a matrix, a carbonate polymeric monomer and an amide group-containing polymeric monomer are copolymerized to form an organic network, and a lithium salt for lithium ion transmission is compounded with an inorganic oxide solid electrolyte to realize organic-inorganic synergistic flame retardance; in addition, the inorganic electrolyte and a polymer chain form a three-dimensional skeleton structure, and a stable composite system is formed through oxygen vacancy anchoring.

To provide artificial expression constructs that selectively drive protein expression.SOLUTION: An artificial expression construct comprising a specific enhancer, a promoter, and a heterologous coding sequence, wherein in one aspect the heterologous coding sequence encodes an effector element or an expressible element, wherein the effector element comprises a reporter protein or a functional molecule, wherein the reporter protein comprises a fluorescent protein, An artificial expression construct is provided wherein the functional molecule comprises a functional ion transporter, an enzyme, a transcription factor, a receptor, a membrane protein, a cellular transport protein, a signaling molecule, a neurotransmitter, a calcium reporter, a channelrhodopsin, a CRISPR / CAS molecule, an editase, a guide RNA molecule, a microRNA, a homologous recombination donor cassette, or a designer receptor exclusively activated with a designer drug.SELECTED DRAWING: Figure 1

The present invention relates to sulfonyl carboxamide derivatives represented by formula (I): wherein R1 represents and aryl group, a cycloalkyl group, a heterocycloalkyl group, or polycyclic group; and R2 represents a bicyclic group. The invention further relates to a pharmaceutical composition comprising the compound of formula (I) in combination with one or more pharmaceutically acceptable excipients. This compound or composition specifically targets ion transporters, ensuring their proper funcitoning and preventing disorders associated with abnormal ion transport.

A system and method for treatment of ischemia limb by operating the sodium-potassium (Na / K) pumps of the ischemia limb to consume one ATP to actively extrude 3 Na+ and pumping in 2 K+ ions, synchronizing the Na / K pump molecules down to individual steps in a pumping cycle and then switching to a noncanonical mode to synthesize one ATP molecule at end of each pumping cycle. The synthesis of ATP molecule compensates the ATP consumed in actively transporting ions. As a result, the zero-consumption of ATP for the electrically modulated Na / K pumps controlled by the system and method of the present invention save the residual limited ATP molecules in the ischemia limb to maintain the living environment of the cells in the ischemia limb, and therefore recover the functions of the limb.

This invention discloses a genetically engineered bacterium producing high levels of butyric acid, its construction method, and its applications. The invention constructs a genetically engineered bacterium producing high levels of butyric acid by overexpressing a ferrous ion transporter protein in Clostridium. Compared to wild-type strains, the genetically engineered bacterium of this invention exhibits enhanced metabolic flux in reactions related to butyric acid synthesis, inhibits the allocation of carbon to byproduct pathways such as acetic acid and lactic acid, and maintains good growth and metabolic activity even under butyric acid stress, thereby prolonging the effective acid production time and improving the stability and final accumulation of butyric acid in the later stages of fermentation. In other words, the genetically engineered bacterium of this invention can increase the proportion of butyric acid in fermentation products under the same substrate conditions, reduce byproduct formation, and lower the difficulty and cost of downstream separation and purification. Furthermore, the genetically engineered bacterium of this invention is robust, suitable for scale-up and industrial applications, and beneficial for the biosynthesis and widespread application of butyric acid.

The invention provides an aramid-based solid polymer electrolyte membrane with hydrogen bond defects and a preparation method and application thereof, and relates to the technical field of material chemistry. The aramid-based solid polymer electrolyte membrane comprises a chemically modified ether chain segment grafted aramid matrix and anhydrous alkali metal salts (such as lithium salts, sodium salts, potassium salts and the like). According to the aramid-based solid polymer electrolyte membrane disclosed by the invention, partial ether chain segment grafting is carried out on NH sites in an aramid framework by virtue of a chemical method, so that local hydrogen bond site defects are constructed; and a local interphase ion transmission channel is constructed through coupling with the high-concentration metal salt, the small molecule ion transporter and the inorganic filler, so that ion transmission is enhanced. The chemical grafting method has a great improvement effect on the film forming process and the ion transmission capability of the aramid fiber material, and is beneficial to popularization of large-scale application of the traditional high-performance aramid fiber material in the field of batteries.

The invention relates to the technical field of medicine synthesis, in particular to copper-cefazolin nanoparticles and a preparation method and application thereof. The copper-cefazolin nanoparticle provided by the invention comprises copper ions and cefazolin coordinated with the copper ions. The copper-cefazolin nano-particles provided by the invention have a relatively strong killing effect on bacteria (staphylococcus aureus), ROS can be generated under an acidic condition to change the permeability of bacterial cell membranes, and meanwhile, the copper-cefazolin nano-particles flow into the bacteria and down-regulate copper ion transporters, so that the copper-cefazolin nano-particles have a long-acting, stable and remarkable antibacterial effect. In addition, the copper-cefazolin nanoparticles can down-regulate inflammatory cytokines, activate peripheral nerves and promote vascular remodeling and hair follicle regeneration under a weakly alkaline condition, and have a good treatment effect on infectious wounds.

Compounds, compositions and methods for inhibiting Syk phosphorylated red blood cell anion transporter band 3 and / or Syk tyrosine kinase. Also disclosed are methods of treating a subject having a disease involving release of microvesicles from blood cells, including alpha-thalassemia or beta-thalassemia, sickle cell disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or glutathione reductase deficiency.

The invention provides that the expression and / or activity of metal ion transporter, such as a Ca2+ / Mn2+ transporter and secretory pathway calcium ATPase 1 (SPCA1) or SPCA2 is associated with the restoration and conservation of Golgi integrity in cells, and with the restoration of Golgi ion concentrations. Provided herein are methods of restoring or maintaining Golgi integrity and methods of modulating Golgi ion concentration in a cell including increasing the expression and / or activity of a metal ion transporter such as SPCA1 or SPCA2 in the cell. The invention further provides methods of treating diseases including neurodegenerative disease and Hailey Hailey disease including increasing the expression and / or activity of a metal ion transporter such as SPCA1 or SPCA2 protein in cells to restore or maintain Golgi integrity and Golgi ion concentration in the cell.

The present invention discloses an antibody against Staphylococcus aureus manganese ion transporter C and its application. The antibody provided by the present invention can specifically bind to MntC protein, can effectively inhibit the growth of Staphylococcus aureus, provides a new idea for the detection of MntC protein and the treatment of related diseases, and has broad application prospects.

The present invention relates to sulfonyl carboxamide derivatives represented by formula (I):wherein R1 represents an aryl group, a cycloalkyl group, a heterocycloalkyl group, or polycyclic group; and R2 represents a bicyclic group. The invention further relates to a pharmaceutical composition comprising the compound of formula (I) in combination with one or more pharmaceutically acceptable excipients. This compound or composition specifically targets ion transporters, ensuring their proper functioning and preventing disorders associated with abnormal ion transport.

The application discloses application of a rice OsHAK22 gene in regulating drought stress tolerance of rice. A high-affinity potassium ion transporter coding gene OsHAK22, and the sequence is shown as SEQ ID NO. 1. The gene can be applied in controlling drought stress tolerance of rice and the like. The application finds the biological function of the high-affinity potassium ion transporter coding gene OsHAK22 in rice through a large number of experiments. After overexpression of the gene, the drought stress tolerance of rice seedlings and booting stages is enhanced. After knockout of the gene, the drought stress sensitivity of rice seedlings and booting stages is caused.

Compounds, compositions and methods for inhibiting Syk from phosphorylating erythrocyte anion transporter band 3 and / or Syk tyrosine kinase. Further disclosed are methods of treating a subject for a disease involving the release of microvesicles from blood cells, including alpha-thalassemia or beta-thalassemia, sickle cell disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency or glutathione reductase deficiency.